NCT06361407 Sensory and Cognitive Predictions, and Their Disruptions in Schizophrenia
| NCT ID | NCT06361407 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Psychothérapique de Nancy |
| Condition | Schizophrenia |
| Study Type | INTERVENTIONAL |
| Enrollment | 68 participants |
| Start Date | 2024-06-28 |
| Primary Completion | 2027-10-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 68 participants in total. It began in 2024-06-28 with a primary completion date of 2027-10-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Disturbances in the sense of self and time could play an important role in the development of psychotic symptoms. Previous work has shown that patients have difficulty preparing to process information on the scale of a second, but are abnormally disturbed by slightly asynchronous information on the millisecond scale. In both cases, the anomalies could explain the patients' unusual experience of time. The hypothesis in neurotypical patients is that small delays or asynchronies asynchronies are treated as irrelevant information and ignored and ignored, whereas in patients suffering from schizophrenia they would disrupt the flow of time. This hypothesis is tested with a new visual illusion.
Eligibility Criteria
Inclusion Criteria: * Male or female; * Age between 18 and 60 inclusive; * Subject having dated and signed the consent form prior to the start of any trial-related procedure (guardian or curator where applicable); * Member of a social security scheme or beneficiary of such a scheme. Exclusion Criteria: * Psychoactive substance use disorders (as defined by the DSM-V) (Diagnostic and Statistical Manual-V); * Use of benzodiazepines, hallucinogens (in the period preceding before inclusion, for a duration equivalent to 5 half-lives of the product) or cannabis (in the 2 months preceding inclusion); * Neurological pathology or sequelae; * Attention deficit hyperactivity disorder (ADHD); * Borderline personality disorder; * Disabling sensory disorders (visual acuity \<0.8); * Person deprived of liberty or under court protection; * Pregnant, parturient or breast-feeding women; * Subjects in a period of exclusion defined by another clinical study.
Contact & Investigator
Anne Giersch, MD PhD
PRINCIPAL INVESTIGATOR
Institut National de la Santé Et de la Recherche Médicale, France
Frequently Asked Questions
Who can join the NCT06361407 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Schizophrenia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06361407 currently recruiting?
Yes, NCT06361407 is actively recruiting participants. Contact the research team at giersch@unistra.fr for enrollment information.
Where is the NCT06361407 trial being conducted?
This trial is being conducted at Marseille, France, Montéléger, France.
Who is sponsoring the NCT06361407 clinical trial?
NCT06361407 is sponsored by Centre Psychothérapique de Nancy. The principal investigator is Anne Giersch, MD PhD at Institut National de la Santé Et de la Recherche Médicale, France. The trial plans to enroll 68 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.